MELBOURNE, Australia, Nov. 15, 2017 — Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX:CYP), is pleased to provide an update on the progress of the clinical trial of its lead Cymerus™ mesenchymal stem cell (MSC) product CYP-001. [Read more…]
Fortuna Fix Announces Series B Financing, Adding Amgen Ventures and Macnguyen Family Office as Shareholders
London, UK and Montreal, Canada, November 8, 2017 (Newswire) –Fortuna Fix (“Fortuna”), a private, clinical-stage Regenerative Medicine company is aiming to be the first to bring to the clinic a patient’s own neural stem cells (autologous) produced by direct reprogramming (“drNPCs”
[Read more…]
Pluristem Partners with Tel Aviv Sourasky Medical Center for Phase I/II Trial in Steroid-Refractory Chronic GvHD
- Tel Aviv Sourasky Medical Center will act as the sponsor of the study
- PLX-PAD cells have demonstrated efficacy in preclinical models of GvHD
HAIFA, Israel, Nov. 06, 2017 — Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, today announced that it has signed an agreement with Tel Aviv Sourasky Medical Center (Ichilov Hospital) to conduct a Phase I/II trial in PLX-PAD cell therapy for the treatment of Steroid-Refractory Chronic Graft-versus-Host-Disease (GvHD).
The trial will be an investigator initiated study. As such, Tel Aviv Sourasky Medical Center will support the study and will be responsible for its design and implementation. Dr. Ron Ram, Director of the Hematology Blood and Marrow Stem Cell Transplantation Unit for the Tel Aviv Sourasky Medical Center will act as principal investigator.
GvHD is a potentially lethal complication of hematopoietic cell transplantation (HCT) from a donor. When a patient receives a donor’s stem cells, the transplanted cells identify the patient’s body as foreign and attack it. The chronic form of GvHD occurs at least 100 days following the transplantation. The GvHD market is predicted to exceed $500 million by 2023. [Read more…]
Top 5 Cord Blood Industry Influencers
Below are our awards for the top five cord blood industry influencers worldwide.
These individuals are all renowned industry experts, innovative thought leaders, and highly sought after speakers, advisors, and board members. Their opinions on cord blood banking topics can substantially alter public perception.
Congrats to those on this list!
Top 10 Most Important iPS Cell Advancesof All Time
In 2006, Shinya Yamanaka and Kazutoshi Takahashi reported the Nobel Prize winning discovery of induced pluripotent stem cells (iPSCs) in Cell, forever changing the landscape of stem cell research. In the 10 years that have since passed, iPSC technology has advanced the fields of drug discovery, toxicology, disease modelling, and cellular medicine.
To celebrate and honor these achievements, this article highlights the the most epic iPSC advances of all time. [Read more…]
- « Previous Page
- 1
- …
- 120
- 121
- 122
- 123
- 124
- …
- 201
- Next Page »